Cipla has announced the launch of its Serroflo salmeterol/fluticasone MDI, a generic version of Advair, in Germany and Sweden. The inhaler will be available in 25/125 mcg and 25/250 mcg versions, both of which will have 120 doses. The Serroflo brand name will be used in Germany; in Sweden, the product will be called Salmeterol/Fluticasone Cipla.” The inhaler is already available in Croatia, where it is marketed as Duohal.
Cipla Europe Head Frank Pieters commented, “With Serroflo we offer in Germany and Sweden an alternative which is effective and efficient and therefore brings many advantages into a market which suffers from limited resources.”
In the announcement, the company asserted that, “With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment.” More launches in Europe are expected over the next year to year and a half.
Read the Cipla press release.
